Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.1 (
pyruvate carboxylase
)
1,516
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To understand the effects of
bcl-2
on glucose metabolism and tumor necrosis factor-alpha (TNF-alpha) mediated cytotoxicity, the activities of glycolytic enzymes (hexokinase, 6-phosphofructo-1-kinase, and pyruvate kinase), lactate dehydrogenase,
pyruvate carboxylase
, and phosphoenolpyruvate carboxykinase were examined with or without TNF-alpha treatment in TNF-alpha sensitive L929 cells and TNF-alpha resistant
bcl-2
transfected L929 cells. In TNF-alpha-treated L929 cells, the activities of the glycolytic enzymes and lactate dehydrogenase greatly increased, but there was no detectable change in phosphoenolpyruvate carboxykinase.
Pyruvate carboxylase
activity decreased by about 25% between 6 and 12 h after TNF-alpha treatment. The activities of the glycolytic enzymes and lactate dehydrogenase in
bcl-2
transfected L929 cells were lower than in L929 cells upon TNF-alpha treatment. On the other hand, the activity of
pyruvate carboxylase
was 20-100% greater after 6 h of TNF-alpha treatment than in the L929 cells. The activity of phosphoenolpyruvate carboxykinase of
bcl-2
trasfected L929 cells was lower by up to 25% than in L929 cells after 12 h. The increase of
pyruvate carboxylase
activity and decrease of phosphoenolpyruvate carboxykinase activity in
bcl-2
transfected L929 cells may contribute to the protective effects of
bcl-2
against TNF-alpha mediated cytotoxicity.
...
PMID:Bcl-2 inhibits tumor necrosis factor-alpha-mediated increase of glycolytic enzyme activities and enhances pyruvate carboxylase activity. 1450 47
